One of the largest and most secretive biotech firms in Cambridge, Moderna Therapeutics, revealed for the first time today plans to develop vaccines for some of the most deadly strains of influenza, a mosquito-borne disease common in Africa and Asia and a drug with potential to treat patients with heart failure.
In an investor presentation Monday in San Francisco, Moderna CEO Stéphane Bancel pulled back the curtain on some of its drugs and vaccines in development for the first time since its founding…
One of the largest and most secretive biotech firms in Cambridge, Moderna Therapeutics, revealed for the first time today plans to develop vaccines for some of the most deadly strains of influenza, a mosquito-borne disease common in Africa and Asia and a drug with potential to treat patients with heart failure.
In an investor presentation Monday in San Francisco, Moderna CEO Stéphane Bancel pulled back the curtain on some of its drugs and vaccines in development for the first time since its founding…